[PHP340] Is Oncology Drug Financial Toxicity A Specific US Issue?

[PHP340] Is Oncology Drug Financial Toxicity A Specific US Issue?

2015 Value in Health

Chouaid, C. | Rémuzat, C. | Caban, A. | Toumi, M. | Volume: 18, Issue: 7, Pages: A573,

Cancer imposes enormous financial burden to society. Direct medical costs were estimated at around €51 billion across European (EU) countries (2009) and $88.7 billion in the United-States (US) (2011). The concept of “financial toxicity” has been first reported by US academic oncologists, Zafar and Abernathy in 2013. It refers to financial distress linked to out-of-pocket payments of costly oncology drugs (OD). This critical concept led to the development of a patient-reported outcome questionnaire by de Souza et al.

https://www.doi.org/10.1016/j.jval.2015.09.1894